Routine prophylactic antibiotic use in the management of snakebite by Tagwireyi, Dexter D et al.
BioMed  Central BMC Clinical Pharmacology
BMC Clinical Pharmacology  2001,  1 :4 Research article
Routine prophylactic antibiotic use in the management of snakebite
Dexter D Tagwireyi1, Douglas E Ball*1 and Charles FB Nhachi2
Address: 1Drug and Toxicology Information Service, Department of Pharmacy, University of Zimbabwe, Box A178, Avondale, Harare, 
Zimbabwe and 2Department of Clinical Pharmacology, Medical School, University of Zimbabwe, Box A178, Avondale, Harare, Zimbabwe
E-mail: Dexter D Tagwireyi - dtagwireyi@healthnet.zw; Douglas E Ball* - dball@healthnet.zw; Charles FB Nhachi - cnhachi@healthnet.zw
*Corresponding author
Abstract
Background:  Routine antibiotic prophylaxis following snakebite is not recommended but
evidence suggests that it may be common practice in Zimbabwe. This study set out to determine
and describe the extent of this practice at Parirenyatwa Hospital, a large teaching hospital in
Zimbabwe
Methods: A retrospective case review (1996 to 1999 inclusive) of all cases of snakebite was
undertaken at Parirenyatwa Hospital. Cases with a diagnosis of snakebite, presenting within 24
hours of the bite and with no complications or concurrent illness were defined as "routine
prophylactic antibiotic use".
Results: From 78 cases which satisfied the inclusion criteria, 69 (88.5%) received antibiotics. Ten
different antibiotics from 6 different classes were used with penicillins the most commonly
prescribed (benzylpenicillin in 29% of cases, alone or in combination). Over 40% of antibiotics were
given parenterally although all patients were conscious on admission. The total cost of antibiotics
used was estimated at US$522.98.
Conclusion: Routine prophylactic use of antibiotics in snakebite at Parirenyatwa Hospital is
common practice. This may highlight the lack of a clearly defined policy leading to wasteful
inappropriate antibiotic use which is costly and may promote bacterial antibiotic resistance. Further
work is required to investigate the reasons for this practice and to design appropriate interventions
to counter it.
Background 
The routine prophylactic use of antibiotics in the man-
agement of snakebite has been advocated and recom-
mended by some authors [1]. This approach has been
based largely on sparse and often conflicting evidence
concerning the bacterial flora of the oral cavity and ven-
om of snakes [2] and the assumption that a snakebite
would result in soft tissue infection at the bite site. The
snakebite victim's skin and clothing, materials used for
first aid treatment, and the hospital environment have
also been implicated as other possible sources of bacteri-
al infection [2]. However, results of studies have failed to
show clinical evidence on the benefit of this prophylactic
use of antibiotics [3,4] and there is a low incidence of
wound infection after snakebite [5]. In view of this, the
routine use of antibiotics is generally not advocated and
can be considered inappropriate, save for cases of snake-
bite associated with local tissue necrosis or gangrene
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[6,7], abscess formation [8], or bullae [9]. This point has
been emphasised by previous authors with regard to
snakebite in Zimbabwe [10,11] as well as by our national
Drug and Toxicology Information Service (DaTIS) [12].
Studies in Zimbabwe have shown that antibiotics are the
most frequently used medication in the management of
snakebite [11,13,14] with some authors suggesting that in
most instances the use of antibiotics for snakebite was
inappropriate and irrational [11,13,15]. However, none of
these studies attempted to establish the extent of routine
prophylactic use of antibiotics in snakebite since they did
not exclude cases where the antibiotics may have been
warranted such as necrotising bite areas, coexisting bac-
terial infections or local complications of snake venom.
In view of this and because of the financial implications,
we studied routine prophylactic antibiotic use in snake-
bite at one of the largest referral hospitals in the country
in order to assess the extent of this practice and to iden-
tify which antibiotics are most commonly used.
Methods 
A retrospective review of all case notes (including both
physician's and nurse's notes) of snakebite was conduct-
ed at Parirenyatwa Hospital, Harare, Zimbabwe for the
period January 1996 – December 1999 inclusive. The di-
agnosis of "snakebite" in all cases was made by emergen-
cy department physicians and records were filed whether
or not patients were admitted to the hospital. The case
notes were traced using the International Classification
of Diseases code 989.5[16] for poisoning by snake venom
or bite. Inclusion criteria for "routine prophylactic anti-
biotic use" required that patients presented to the hospi-
tal on the day of or the following day to the bite and did
not exhibit complications or evidence of necrosis e.g.
darkening of the bite site, abscess formation, bullae for-
mation or any other sign of infection which would re-
quire antibiotics. If no abnormalities were mentioned in
the case notes it was assumed that none were present.
Any patients presenting more than a day after the snake-
bite were excluded from the analysis since they were as-
sumed to be seeking treatment because of complications
and not due to the bite itself and therefore any therapy
given could not be defined as routine.
Data was recorded and assessed on a standard data col-
lection sheet by a clinical toxicologist (DT) from the poi-
sons information centre. This data included the date that
the bite occurred, date that patient presented to the hos-
pital, antibiotic therapy given on admission and/or in the
Emergency Department, the presence of coexisting ill-
nesses and/or injuries and any recorded local signs and
symptoms at the bite site. Whilst the hospital computers
could select case numbers by ICD-9 code, the laborious
nature of locating and browsing records by hand and
manpower limitations precluded validation of the data
extraction procedure by a second person.
Financial implications 
It is the policy of the Pharmacy Department at Parireny-
atwa Hospital to supply a full one week course of oral an-
tibiotics to all hospital inpatients for capsules and tablets
and a three day course for patients on parenteral antibi-
otics. For children, a 100 ml suspension is normally sup-
plied. An estimate of cost of antibiotics prescribed for
adults was calculated based on the retail cost of the drug
(wholesale cost + 50%), the defined daily dose (DDD) for
the antibiotic and the hospital pharmacy policy of sup-
plying antibiotics. To estimate the cost of antibiotics pre-
scribed for children (under 12 yrs), it was assumed that
the average daily dose was half that of the DDD in adults.
For oral doses, the cost of a 100 ml suspension of the an-
tibiotic was used. The costs were calculated using prices
as valid on 1st July 2000 and the exchange rate of
US$1=Z$38.
Results 
A total of 103 cases diagnosed as due to snakebite for the
study period were identified. Nineteen cases were ex-
cluded (15 on the basis that they had presented two days
or more after the bite, in 3 cases the date of snakebite was
not recorded and 1 was excluded as the snake had spat
into the patient's eyes and not actually bitten them).
Therefore a total of 84 patients presented either on the
day of the bite or on the following day. Of these, 3 had
necrosis and 2 abscess formation at the bite site and were
excluded as these symptoms were considered complica-
tions warranting antibiotic use and therefore did not
warrant "routine prophylactic antibiotic use". Four cases
had a coexisting illness (2 hypertensive, 1 peptic ulcer
disease on antacid therapy and 1 with a productive cough
on no drugs). The patient with the productive cough was
excluded as this may have warranted antibiotic use. De-
tails of the excluded patients and the antibiotics they re-
ceived are shown in Table 1.
In all, 78 cases satisfied the inclusion criteria (Table 2) as
potential candidates of routine prophylactic antibiotic
use. Sixty-nine (88.5%) received antibiotics (31 male; the
sex of one case not recorded). The ages in these cases
ranged from 5 to 62 years (n = 68; median 21.5 yr) with
14 cases being below the age of 12 years. All patients were
conscious on admission. The length of hospital stay
ranged from 1 to 16 days (n = 68; median 2.5 days). Only
two patients received antivenin of which one also re-
ceived an antibiotic (amoxycillin orally). No culture and
sensitivity tests were done before instituting the antibi-
otic therapy in any of the cases and there were no fatali-
ties in the series.BMC Clinical Pharmacology 2001, 1:4 http://www.biomedcentral.com/1472-6904/1/4
Table 1 :  Case details of patients who were excluded from the definition of routine antibiotic use 
Age (yrs) Sex (M/F) Reason for exclusion Antibiotics on 
admission
Length of hospital 
stay (days)
Antibiotics on 
discharge
43 M Darkening of bite site Benzylpenicillin 4 none
16 M Darkening of bite site Benzylpenicillin 4 none
4 M Darkening of bite site Amoxycillin 2 none
7 M Abscess Benzylpenicillin 2 none
Gentamicin
58 M Abscess Benzyl penicillin 6 none
Cloxacillin
Metronidazole
48 M Productive cough Ampicillin 2 Amoxycillin
Table 2 :  Local clinical signs and symptoms of all study cases of suspected snakebite 
Local clinical signs and symptoms Cases presenting Cases receiving antibiotics
(n = 78) (n = 69)
Pain with swelling 39 36
Pain with swelling and warmth 14 13
Swelling only 11 9
Pain only 6 6
No signs of snakebite 4 3
Fang marks only 2 1
Pain with swelling and incision* 11
Swelling with warmth 1 1
Cuts made by traditional healers in Zimbabwe
Table 3 :  Frequency of use of inappropriate routine antibiotics. 
Drug Cases receiving oral 
antibiotics
             Cases receiving parenteral antibiotics Total
Adults Children Adults Children
Benzylpenicillin 0 0 24 7 31
Amoxycillin* 1 4 600 2 0
Cloxacillin 9 3 3 0 15
Ampicillin * 5 260 1 3
Metronidazole 10 0 0 1 11
G e n t a m i c i n 0 0325
C l i n d a m y c i n 2 0002
Chloramphenicol* 4 0004
P e n i c i l l i n  V 3 0003
Erythromycin* 3 0003
T o t a l 5 0 1 13 61 0 1 0 7
*Drugs considered as broad spectrum antibioticsBMC Clinical Pharmacology 2001, 1:4 http://www.biomedcentral.com/1472-6904/1/4
Antibiotics utilised 
A total of 10 different types of antibiotics (from 6 classes
namely, penicillins, macrolides, chloramphenicols,
aminoglycosides, lincosamides and nitro-imidazoles)
were used (Table 3). Penicillins were the most frequently
used antibiotics (76.6% of all antibiotics used) with ben-
zylpenicillin being the most widely prescribed (29.0% of
all cases) either alone or in combination (Tables 3 and 4).
A large proportion of the antibiotics utilised (42.2%)
were given parenterally and 37.4% were broad-spectrum
antibiotics (Table 3).
The total cost of antibiotics for adult patients was calcu-
lated to be Z$3525.84 for oral and Z$12285.07 for
parenteral preparations. The cost of antibiotic therapy in
paediatric patients was Z$933.36 for oral and Z$3128.69
for parenteral doses. The total cost of antibiotics used
was therefore estimated to be Z$19872.96 (US$522.98).
Discussion 
Venomous snakes in Zimbabwe fall into four main fami-
lies namely elapidae (cobras and mambas), colubridae
(boomslang), viperidae (adders or vipers) and atractas-
pididae (asps) and have been extensively described else-
where in the literature [10,12,14,15]. It is claimed that, of
the venomous snakes, cytotoxic adder bites e.g. puff
adder (Bitis spp.) are the most common, followed by
neurotoxic cobra (Naja spp.) and mamba (Dendroasapis
spp.) bites with haemotoxic boomslang (Dispholidus ty-
pus) bites rarely seen[13], a large number of non-venom-
ous snakes also abound which may be responsible for
bites. The incidence of non-venomous bites and/or "dry"
bites by venomous snakes is taken to be high in the
catchment area of Parirenyatwa Hospital, an assumption
supported by the fact that only two cases received anti-
venin in this series. Despite the availability of informa-
tion on dangerous snakes in Zimbabwe, those
responsible for the greater proportion of bites are seldom
identified by health care professionals. This can be at-
tributed to the fact that most bites occur in the night
when visibility is low. In addition, even if the culprit
snake is seen, patients presenting to health facilities are
seldom able to identify it, and rarely bring dead snakes
along with them. Treatment of snakebite at health care
facilities in Zimbabwe is therefore nearly always based
on presenting clinical signs and symptoms.
Whilst this study was set out to examine and describe the
extent of routine prophylactic antibiotic use in snakebite,
it is useful to consider those situations in which antibiot-
ic use is appropriate. Necrosis at the snakebite area pro-
vides an ideal setting for the proliferation of micro-
organisms, a situation which may be worsened by the use
of a tourniquet [2,17]. However, bacterial infection is not
always present at the necrotised snakebite site as evi-
denced by the absence of bacterial growth from necrosis
due to bites from the Southern African puff adder (Bitis
arietans) and rhombic nightadder (Caucus rhombeatus)
[7]. Moreover, cultures of the oral cavities and venoms of
different snakes [1,2,18], and swabs from necrotic bite
sites and abscesses have shown a wide variety of both
aerobic (Gram positive and Gram negative) and anaero-
bic bacteria including Clostridium spp [3,7,8,17,19]. In
view of this, antibiotic therapy after necrosis should be
based on cultures and antibiotic susceptibility testing, a
point which has been stressed by other workers [2,20].
The 3 patients (excluded from the analysis) who present-
ed with necrosis in the present study all received empiric
antibiotic therapy and no culture and sensitivity tests
were done despite the availability of facilities to carry
these tests out at the hospital. It has been suggested that
if antibiotics are to be used prophylactically for snakebite
in Southern Africa, then Gram-negative aerobic Entero-
bacteriaceae and Staphylococcus spp. must be covered
[7]. However since the range of bacteria from the venom
and oral cavities of snakes vary with geographic area, the
species and oral health of the snake [21], this cannot be
easily extrapolated to snakes in Zimbabwe. Moreover,
the "blind" use of antibiotics covering such a broad spec-
trum of activity may promote the emergence of antibac-
terial drug resistance.
Bacteria are a major cause of abscess formation but the
role of prophylactic antibiotics to prevent their forma-
tion is questionable [22]. Proteolytic effects of some
snake venoms may cause local reactions that also have a
role to play in the pathogenesis of abscess formation [8].
The two patients (excluded) who presented with abscess
formation both received antibiotics. The use of antibiot-
ics may prevent dissemination of the infection and accel-
erate healing [8]. However, as in the case of suspected
infection of necrotic areas and for the same reasons, it is
desirable to perform culture and sensitivity tests before
commencing antibiotic therapy.
Table 4 :  Common antibiotics combinations found in the study. 
Antibiotic combination* No. of cases
benzylpenicillin alone 8
amoxycillin alone 7
benzylpenicillin and metronidazole 5
cloxacillin alone 3
benzylpenicillin and cloxacillin 3
ampicillin alone 2
benzylpenicillin and gentamycin 2
* reflects only those combinations used in 2 or more casesBMC Clinical Pharmacology 2001, 1:4 http://www.biomedcentral.com/1472-6904/1/4
There is little clinical evidence of the benefit of prophy-
lactic antibiotics after snakebite [3–5] and the routine
use of antibiotics is not advocated except for cases of
snakebite associated with complications or signs of in-
fection [6–9]. In the present study, well over three quar-
ters of patients received routine prophylactic antibiotic
therapy (88.5%). The reason for this may be attributed to
genuine concern over the occurrence of tissue infection
after snakebite even where no local complications due to
the venom or otherwise are present. However, it is also
possible that antibiotics are given to patients simply as a
form of reassurance to make the patients believe that
they were receiving proper treatment. The relatively
large proportion of patients (42.2%) who received
parenteral antibiotics despite all patients being con-
scious on admission may support this speculation since
injections may be viewed as superior treatment than oral
medicines in some cultures [23]. The fact that both pa-
tients who received antivenin did not receive parenteral
preparations suggests this may be an important consid-
eration. The use of antibiotics for the purposes of proph-
ylaxis against infection accounts for most misuse of these
drugs. Zimbabwe is a developing country with limited
medical and financial resources, and rational use of
drugs is promoted in the National Drug Policy [24] in or-
der to better manage these resources. Routine prophy-
lactic antibiotic use for snakebite should therefore be
limited only to cases where they are truly needed as doc-
umented in the literature [4,7–9]. Using antibiotics rou-
tinely for snakebite is not cost effective and puts undue
financial pressure on patients who have to pay for antibi-
otics they do not really need. This is more so with the
routine use of parenteral antibiotics which are generally
more costly (exemplified by our results) and carry risks
inherent to invasive procedures. In this study, we esti-
mated the total cost of the drugs to the patient to be
US$522. This is an underestimate of the actual costs of
antibiotic therapy as it excludes syringes, needles, health
worker time and similar costs and ignores devaluation
and depreciation of the Zimbabwe dollar between 1996
and 2000. Moreover, the emergence of antibiotic resist-
ance is primarily due to excessive and often unnecessary
use of antibiotics in humans and animals[25], high rou-
tine prophylactic use of antibiotics in snakebite as dem-
onstrated in this study may therefore lead to antibiotic
resistance with implications on the use of these drugs in
conditions where they are truly needed. Although the
number of cases in this series was relatively small and
may not impact significantly on antibiotic resistance in
itself, when looking at the problem from a national view
point and taking into consideration hospitals at lower
levels of care e.g. district hospitals, this may still be an
relevant concern.
The wide variety of antibiotics used routinely at the study
hospital is also of concern. A previous retrospective
study at six referral hospitals also demonstrated that an
array of antibiotics were used in the management of
snakebite in Zimbabwe [13]. Studies from other regions
of the world do not appear to follow the same pattern.
These include the Asir region of Saudi Arabia and East-
ern Ecuador for instance where only ampicillin alone or
in combination with another antibiotic were used for
snakebite[3,26] This variety in antibiotic prescribing for
snakebite in Zimbabwe indicates the lack of a clearly de-
fined policy with regards to this issue. Taken together
with the high use of broad spectrum antibiotics (espe-
cially amoxycillin and ampicillin), it also demonstrates a
lack of knowledge with regards to which pathogenic bac-
teria exist in the oral cavities of snakes in the region and
in what instances infection is most likely to occur. Over-
use of broad spectrum antibiotics especially where they
are really not required is irrational and has been cited as
a major reason for the growing world-wide resistance of
bacteria to antibiotics. [27] Whilst a large number of
broad spectrum antibiotics were used, it is interesting to
note that benzylpenicillin alone was the most widely
used antibiotic at the study hospital, something which
has been reported at other referral hospitals in Zimba-
bwe [4,28]. It is possible that the antibiotic is preferred
due to its parenteral route of administration and relative
safety as compared to other injectable antibiotics. It is
also possible that this narrow spectrum antibiotic was fa-
voured by some prescribers because of concern about
promoting drug resistance by using broad spectrum
agents.
The definition of "routine prophylactic antibiotic use" in
the present study was based mainly on retrospective as-
sessment of recorded local clinical signs and symptoms,
a methodology which has inherent weaknesses. Since
health workers at the time were not aware of the study,
records may be incomplete with some observations not
being included in patient notes. Thus there may have
been omission of important local clinical signs from the
records and if no abnormalities were recorded it was as-
sumed there were none. Furthermore, swelling, regard-
less of severity, was not considered as one of the local
clinical signs warranting the use of antibiotics and could
have excluded true bacterial cellulitis without sepsis.
However, this bias was reduced by excluding all cases
presenting more than a day after the snakebite. Exclud-
ing patients presenting a day after the bite may have fur-
ther reduced this bias, but this would have resulted in us
missing bites which occurred in the night and where the
patient presented to the hospital the next morning –
most snakebites are reported to occur in the later hours
of the day in Zimbabwe [4,11]. Pyrexia, was also not con-
sidered as one of the clinical presentations warrantingBMC Clinical Pharmacology 2001, 1:4 http://www.biomedcentral.com/1472-6904/1/4
the use of antibiotics. This was in view of the fact that de-
spite reports of bacteria in snake venom[2] which would
lead to systemic infection, it is in fact sterile like other
body fluids [9,18]. Some authors have even suggested
that some snake venoms may possess antibacterial prop-
erties [7,29]. Pyrexia after snakebite is said to be rarely
due to sepsis [15] and is more likely to be a consequence
of the venom itself rather than systemic infection. How-
ever, by excluding fever, we may have missed some infec-
tions. Each of these limitations alone or in combination
could lead to over-estimation of prophylactic antibiotic
use since there may have been additional cases which re-
quired antibiotics. However, they are unlikely to explain
the high antibiotic prescribing observed.
There may also have been misclassification of records i.e.
some cases of snakebite not being filed under the rele-
vant ICD-9 code which was used to locate the case notes.
Ideally, the extraction procedure could have been vali-
dated by browsing all patient records over a set time pe-
riod to observe that all snakebite cases were filed
appropriately. However, the hospital computer system
does not offer simple search and browse methods – once
a record number is identified it has to be located physi-
cally and browsed by hand. The logistics of this and lim-
itations in manpower made validation unrealistic.
However, even if some cases of routine antibiotic proph-
ylaxis in snakebite were missed, this does not reduce the
importance of the findings.
Conclusions 
Routine prophylactic use of antibiotics in the manage-
ment of snakebite is common at Parirenyatwa Hospital.
This is probably as a consequence of the lack of a clearly
defined policy with regards to the exact role of antibiotics
in the management of snakebite in Zimbabwe. This prac-
tice may lead to wastage of medical resources and put
undue financial pressure on the patient who has to pur-
chase unnecessary drugs. This is especially pertinent in
developing countries such as Zimbabwe. Furthermore,
culture and sensitivity tests should be performed before
commencing therapy since bacterial flora in snakes vary
greatly, there are chances that necrotic areas may not get
infected, and the antibiotics are not being used in life-
saving situations. This will reduce overuse of these drugs
with implications for the emergence of bacterial drug re-
sistance and adverse reactions in patients. Educational
and/or managerial interventions are required to address
this situation, but these will need to be complemented by
an assessment of the motivations underlying the pre-
scribing habits observed. We trust that this work will also
serve as the basis for follow up studies investigating the
impact of guidelines on the use of antibiotics in snakebite
and to prospective studies of the effect of antibiotics on
infection following snakebite.
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